Vor Biopharma has pivoted from oncology to autoimmune disease therapeutics by licensing global rights to telitacicept, a fusion protein approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. Alongside, the company has appointed Jean-Paul Kress as CEO and secured $175 million in private equity financing. This strategic redirection follows prior layoffs and clinical program wind-downs. Telitacicept targets BAFF and APRIL cytokines, previously validated targets in immunology, reflecting increased biotech collaborations sourcing innovation from China to global markets.